R. Matkowski

Metabolism alterations accompany the invasive phenotype of melanoma cells resistant to BRAF/MEK inhibitors.

Mutations in the BRAF (B-raf serine-threonine-protein kinase) gene occur in the majority of melanoma patients and significantly contribute to the progression of the disease. One of the most commonly used methods for treating melanoma is the use of BRAF and MEK (mitogen-activated protein kinase kinase) inhibitors. Unfor...